We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Cancer Vaccine Collaborative Launched

By Biotechdaily staff writers
Posted on 10 Oct 2002
A research program to improve the way cancer vaccines are developed has been formed by a network of investigators from six New York (NY, USA) medical centers, who are working together as the Cancer Vaccine Collaborative (CVC) to conduct a series of early-stage clinical trials on cancer vaccines. More...
The CVC was launched at the International Cancer Immunotherapy Symposium in New York by two New York research groups: the Cancer Research Institute (www.cancerresearch.org) and the Ludwig Institute for Cancer Research (www.licr.org).

The CVC will test vaccines for several cancer types, including melanoma, sarcoma, and nonsmall cell lung, ovarian, prostate, and bladder cancers. All share the cancer/testis antigen NY-ESO-1, a special marker found almost exclusively in cancer cells. In certain tumors, the marker can become abnormally expressed, acting as a highly specific target for immune cells to attack. Although antigens alone do not elicit a strong enough response to destroy tumors, the researchers hope that vaccinating cancer patients with NY-ESO-1 can help the immune system finish the job.

The participating investigators include researchers from Columbia Presbyterian Medical Center, New York Weill Cornell Medical Center, Mount Sinai School of Medicine, Memorial Sloan-Kettering Cancer Center, and New York University Cancer Institute.

Unlike conventional vaccine trials, where data from one trial are often incomparable to data from another because of uncontrolled variables, CVC trials will use standardized tests to evaluate different ways to deliver the same vaccine agent. This methodology will allow for direct comparison with other CVC trials and show why certain vaccine strategies might result in a more robust immune response while others might not. The studies will be coordinated and conducted in parallel with each other rather than sequentially.

"Testing different vaccine strategies at one time will allow us to more quickly identify the most promising anticancer therapies,” said Dr. Eric Hoffman, director of clinical trials at the Ludwig Institute for Cancer Research. "And because all the research is done using the same methods and techniques, the Cancer Vaccine Collaborative will ensure that data from one trial site can be readily and confidently compared to that of another site.”




Related Links:
Cancer Research Institute
Ludwig Institute

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.